Veeva Systems Inc. VEEV
Composite 61/100; the shares have moved about 49% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 31/100 — a moderate mark against it.
Balance-sheet strength ranks 96/100 — a strong point in its favour. Growth ranks 78/100 — a strong point in its favour. Momentum ranks 53/100 — a slight point in its favour.
Valuation ranks 31/100 — a moderate mark against it.
What the company does Veeva Systems provides cloud-based software for life sciences, spanning commercial, medical, clinical, regulatory, and quality functions. Its Commercial Cloud (CRM, PromoMats, Crossix) and Development Cloud (Clinical, Safety, RIM) serve pharma and biotech globally.
Key financials Revenue grew 16.3% and EPS 25.9% YoY. Margins are strong: gross 75.0%, operating 29.6%, net 29.3%. ROE is 14.4% and ROA 7.6%. Debt/equity is 0.02 with net cash; current ratio 5.46.
Stock health Momentum is mixed: +58.71% (3m), +52.02% (6m), but -5.76% (12m) and -10.89% below 52w high. RSI(14) at 74.90 signals overbought conditions. Sideravia scores: Quality 68.1, Growth 77.3, Strength 94.8, Valuation 26.2.
Price vs fair value The stock trades at a discount of 6.30% versus the analyst mean target of 294.07. - Subscription revenue grew 16% with GAAP operating income up 40% (Aug 29 headline). - Earnings beat refocused valuation narrative (Aug 28 headline). - CRM wins and AI expansion highlighted in Q2 deep dive (Aug 28 headline). - Truist Securities positive on execution across CRM, AI, and Commercial Cloud (Aug 27 headline).
Looking forward Forward P/E of 31.15 and PEG of 0.64 suggest growth is priced at a premium, while valuation percentile (26.2/100) indicates rich relative pricing. Margin sustainability and AI-driven adoption remain key watchpoints.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.